The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys

Sodium-glucose co-transporter (SGLT)-2 inhibitors were initially developed for management of type 2 diabetes but have been shown to offer improved outcomes in heart failure, a condition in which concomitant chronic kidney disease (CKD) is common. Randomised controlled trials initially demonstrated p...

Cijeli opis

Bibliografski detalji

Glavni autori:	Eirini Lioudaki, Jennifer Ruth Joslin, Eirini Trachanatzi, Emmanuel Androulakis
Format:	Artigo
Jezik:	Inglês
Izdano:	IMR Press 2022-03-01
Serija:	Reviews in Cardiovascular Medicine
Teme:	sodium-glucose co-transporter (sglt)-2 inhibitors heart failure chronic kidney disease (ckd)
Online pristup:	https://www.imrpress.com/journal/RCM/23/3/10.31083/j.rcm2303082
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!